Arcus Biosciences RCUS
NYSE RCUS
$29.62 -0.51 (-1.69%)
As of: Sep 4, 2026 · 12:48 PM EDT

Arcus Biosciences (RCUS) Non Operating Investment Income (2018 - 2020)

Analysis

Arcus Biosciences (RCUS) Non Operating Investment Income (2018 - 2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Vertex Pharmaceuticals 139.76 Bn 131.91 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.72 Bn 77.72 Bn 3.93 Bn -
3 Argenx Se 63.56 Bn 58.38 Bn 1.37 Bn -
4 Moderna 57.87 Bn 52.73 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - -
6 BeOne Medicines 40.08 Bn 34.98 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.50 Bn 32.20 Bn 992.69 Mn -
8 Royalty Pharma 28.54 Bn 27.70 Bn - -
9 Insmed 27.49 Bn 26.33 Bn 358.27 Mn -
10 Arcus Biosciences 3.73 Bn 3.03 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 1.50 Mn
Jun 30, 2020 131,000.00
Mar 31, 2020 482,000.00
Jun 30, 2018 1.23 Mn